YF476
Sponsors
Columbia University, Trio Medicines Ltd.
Conditions
Barrett's EsophagusChronic Atrophic GastritisHypergastrinaemiaHypergastrinemiaReflux OesophagitisType I Gastric CarcinoidsZollinger-Ellison Syndrome
Phase 1
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
CompletedNCT01538784
Start: 1996-05-31End: 1996-06-30Updated: 2012-02-24
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
CompletedNCT01538797
Start: 1996-07-31End: 1996-08-31Updated: 2012-02-24
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
CompletedNCT01597674
Start: 1997-04-30End: 1997-06-30Updated: 2012-05-14
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
CompletedNCT01599858
Start: 1996-08-31End: 1996-10-31Updated: 2012-05-16
Effect of Repeated Doses of YF476 on Stomach Acidity
CompletedNCT01601405
Start: 2001-10-31End: 2001-11-30Updated: 2012-05-18
Effect of Single Doses of YF476 on Stomach Acidity
CompletedNCT01601418
Start: 2001-10-31End: 2002-01-31Updated: 2012-05-18
Effects of YF476 and Rabeprazole on Gastric Function
CompletedNCT01699113
Start: 2006-08-31End: 2007-06-30Updated: 2012-10-03
Phase 2
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
CompletedNCT01298999
Start: 2010-06-30End: 2017-12-31Updated: 2021-11-23
YF476 and Type I Gastric Carcinoids
CompletedNCT01339169
Start: 2011-01-04End: 2013-12-10Updated: 2019-08-19
YF476 and Type I Gastric Carcinoids (Norway)
TerminatedNCT01444014
Start: 2011-06-30End: 2012-05-31Updated: 2015-05-15
YF476 and Type II Gastric Carcinoids
TerminatedNCT02454075
Start: 2011-04-11End: 2012-06-22Updated: 2021-01-29
YF476 in Barrett's Esophagus
CompletedNCT02597712
Start: 2013-05-15End: 2017-12-27Updated: 2021-04-12